Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM)

201744 citationsJournal Articlebronze Open Access

Authors

Timothy R. Deer

Richard Rauck · Carolinas Pain Institute

Philip Kim · International Spine, Pain & Performance

Michael Saulino · Moss Rehabilitation Hospital

Mark S. Wallace · University of California, San Diego

Eric Grigsby · Napa Valley College

I‐Zu Huang · Jazz Pharmaceuticals (United States)

Abstract

Greater improvements in efficacy outcomes were observed when ziconotide was initiated as first-line intrathecal therapy vs. not first intrathecal agent in pump. The adverse event profile was consistent with the ziconotide prescribing information.

Topics & Keywords

Pain Management and Opioid Use Pain Mechanisms and Treatments Pediatric Pain Management Techniques

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Pain Practice

Volume 18, Issue 2, pp. 230-238

DOI: 10.1111/papr.12599

Field-Weighted Citation Impact: 5.32